Intellia Therapeutics is trading 5.02% lower at $12.11, with biotech-sector weakness providing context, though the precise cause is unconfirmed.
- No company announcement dated October 6 was identified in the reviewed sources.
- Barclays initiated coverage that day with an Underweight rating and an $8 price target; the available report does not confirm it caused the decline.
- XBI was down 2.50% during the regular session, while major U.S. indexes were higher.